<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81988">
  <stage>Registered</stage>
  <submitdate>1/05/2007</submitdate>
  <approvaldate>11/05/2007</approvaldate>
  <actrnumber>ACTRN12607000255482</actrnumber>
  <trial_identification>
    <studytitle>Efficacy and safety of a Chinese herbal medicine formula in the management of simple obesity: Randomised placebo-controlled clinical trial</studytitle>
    <scientifictitle>Efficacy and safety of a Chinese herbal medicine formula in the management of simple obesity: Randomised placebo-controlled clinical trial</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil Known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Obesity</healthcondition>
    <conditioncode>
      <conditioncode1>Diet and nutrition</conditioncode1>
      <conditioncode2>Obesity</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Randomised Double-blind Placebo-controlled trial
Each 500 mg capsule of Chinese herbal formula granule will contain Camellia sinenis (40%), Cassia obtusifolia (40%) , Sophora Japonica (20%).</interventions>
    <comparator>The placebo capsule will be herbal starch that contains no active substances, which will have an identical appearance to the real herbal capsule. The granules of the formula and placebo will be in a standard capsule form produced by a manufacturer that holds TGA approved Good Manufacturing Practice (GMP) certificate.
The subject will be asked to take four capsules, three times daily for the period of 12 weeks.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Subjects will be monitored for changes in anthropometric measurements: weight, body mass index (BMI), waist circumference, waist to hip ratio and body fat.</outcome>
      <timepoint>Assessments will be taken every 2 weeks: baseline, every 2 weeks until 12 weeks after the start of the intervention.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The secondary endpoints include specific quality of life questionnaire: Weight-Related Symptom Measure (WRSM) and Obesity &amp; Weight-Loss Quality of Life measure (OWLQOL) and blood pressure . </outcome>
      <timepoint>These assessments will be taken every 2 weeks with the time points:  baseline and every 2 weeks until 12 weeks after the start of the intervention.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serological data: Cholesterol, low density lipoprotein (LDL), high density lipoprotein (HDL), triglycerides, fasting insulin and glucose insulin sensitivity (HOMA-IR).</outcome>
      <timepoint>These assessments will be carried out at the baseline and  end of week 12 of intervention.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety assessments of  renal tests include Sodium, Potasium, Chlorite, Bicarbonate, Urea and Creatinine; and liver function tests are Total Bilirubin, Alanine Aminotransferase (ALT), Aspartate Aminotrasferase (AST), Alkaline Phosphotase (ALP), Gamma Glutamyl Transferase (GGT),Total protein, Albumin, Globulin.</outcome>
      <timepoint>Will also be carried out by a pathology laboratory service at the baseline and  end of week 12 of intervention.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria> Subjects have BMI greater than 30 kg/m2;Not involved in other clinical trials for the treatment of obesity; Agree to avail themselves for the period of the study; and Provide written consent for participation.  </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Subjects with one or more of the following conditions will be excluded from study:Loosing more than 5kg in the past 3 months;Endocrine disorders other than type 2 diabetes mellitus; Uncontrolled hypertension; Autoimmune or cardiovascular diseases or carrying pace-maker; Lactating or pregnant women; Those using drugs affecting the central nervous system or lipid lowering drugs;Obesity known caused by pharmacotherapy;Therapy for weight control in the last 6 months;Kidney or hepatic disease;Unable to read or understand English.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>central randomisation by computer off site</concealment>
    <sequence>Simple randomisation by using a randomization table created by a computer software</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>clinician, assessor and participants are blinded</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/06/2007</anticipatedstartdate>
    <actualstartdate>1/06/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate>30/11/2008</actualenddate>
    <samplesize>80</samplesize>
    <actualsamplesize>92</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Prof. Charlia Xue</primarysponsorname>
    <primarysponsoraddress>School of Health Sciences
RMIT University</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>RMIT University</fundingname>
      <fundingaddress>Plenty Rd 
Bundoorra</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Windermere foundation</fundingname>
      <fundingaddress>48 Webb Street
Narre Warren, VIC 3805</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Prof. Yung Hsien Chang</sponsorname>
      <sponsoraddress>Nil Known</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Trial will involve 80 obese subjects with BMI above 30. It will be randomised placebo controlled trial. Subjects will take Chinese herbal capsules for 12 weeks. The endpoints will be evaluated every 2 weeks.</summary>
    <trialwebsite />
    <publication>1. Lenon , G; Li, K; Yang Li, C G; Cohen, M; Mann, N; Dacosta, C; Chang, Yung-Hsien; Xue, C. (2012). Efficacy and safety of a Chinese herbal medicine formula in the management of simple obesity: A randomized, placebo-controlled clinical trial. Evidence-base Complementary and Alternative Medicine.
2.	Li, K., Yang, A. W., Xue, C. C. L., Lenon, G. B. (2013). Effects of traditional Chinese manual acupuncture for treatment of obesity: A systematic review. Australia and New Zealand Obesity Society (ANZOS) conference, Melbourne Australia.
3.	Li, K., Yang, A. W., Xue, C. C. L., Lenon, G. B. (2013). Effects of traditional Chinese manual acupuncture for treatment of obesity: A systematic review. FCMA conference, Melbourne Australia.
4.	Lenon , G; Li, K; Yang Li, Zhou, W (2012). Characteristics of obese individuals in Northern Melbourne suburbs: Screening assessment of potential subjects of Chinese herbal medicine clinical trial for simple obesity. ANZOS 2012. Auckland, New Zealand.
5.	Lenon , G; Li, K; Yang Li, C G; Cohen, M; Mann, N; Dacosta, C; Chang, Yung-Hsien; Xue, C. (2010). Efficacy and safety of a Chinese herbal medicine formula in the management of simple obesity: A randomized, placebo-controlled clinical trial. 11th International Congress on Obesity. International Association for the Study of Obesity 11, 812831. Stockholm, Sweden.

</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Melbourne Institute of Technilogy University, Clinical Trial Laboratory</ethicname>
      <ethicaddress>Plenty Rd, Bundoora</ethicaddress>
      <ethicapprovaldate>28/03/2007</ethicapprovaldate>
      <hrec>04/07 Lenon</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>George Lenon</name>
      <address>RMIT University
Building 202.4.13
Plenty Rd
Bundoora VIC 3083</address>
      <phone>+61 3 99256587</phone>
      <fax>+61 3 99257178</fax>
      <email>george.lenon@rmit.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>George Lenon</name>
      <address>RMIT University
Building 202.4.13
Plenty Rd
Bundoora VIC 3083</address>
      <phone>+61 3 99256587</phone>
      <fax>+61 3 99257178</fax>
      <email>george.lenon@rmit.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>George Lenon</name>
      <address>RMIT University 
Plenty Rd
Bundoora</address>
      <phone>99256587</phone>
      <fax />
      <email>george.lenon@rmit.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>